{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-127054","form_type":"8-K","ticker":"LITS","cik":"0001262104","company_name":"Lite Strategy, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.924557+00:00","generated_at":"2026-05-30T00:17:46.876861+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"MEI Pharma reports $26.9M cash, no debt; continues strategic alternatives review","bullets":["Cash, cash equivalents and short-term investments at Sept 30, 2024: $26.9M; no outstanding debt.","Strategic alternatives review ongoing; Oppenheimer & Co. acting as exclusive financial advisor.","Reduction-in-force initiated as part of cash preservation efforts; further stages planned.","No assurance that any transaction will result; updates only if Board determines disclosure appropriate."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-127054","json":"https://secwatch.observer/filing/0000950170-24-127054.json","markdown":"https://secwatch.observer/filing/0000950170-24-127054.md","text":"https://secwatch.observer/filing/0000950170-24-127054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1262104/000095017024127054/0000950170-24-127054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1262104/000095017024127054/meip-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:17:46.876861+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}